Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation

The development of nonvitamin K antagonist oral anticoagulants (NOACs) has been a major advance in therapy for patients requiring oral anticoagulation, particularly for long-term indications such as stroke prevention in atrial fibrillation (AF). The NOACs are generally easier to dose and manage due to less heterogeneity of effect across individuals and fewer drug and food interactions, compared with warfarin. However, the treatment effect of NOACs may vary based on important patient characteristics, particularly renal function.
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research